Jason Christiansen

Safety and Antitumor Activity of the Multitargeted Pan-TRK, ROS1, and ALK Inhibitor Entrectinib: Combined Results from Two Phase I Trials (ALKA-372-001 and STARTRK-1)

Alexander Drilon, Salvatore Siena, Sai‐Hong Ignatius Ou et al. · Cancer Discovery · 2017 · 817 citations · Full text

Medicine, Oncology, Pharmacology +16

Multiplexed protein profiling on microarrays by rolling-circle amplification

Barry Schweitzer, Scott Roberts, Brian G. Grimwade et al. · Nature Biotechnology · 2002 · 571 citations · Full text

Life Sciences, Biochemistry, Molecular Biology +11

ALK, ROS1, and NTRK Rearrangements in Metastatic Colorectal Cancer

Filippo Pietrantonio, Federica Di Nicolantonio, Alexa B. Schrock et al. · JNCI Journal of the National Cancer Institute · 2017 · 324 citations · Full text

Medicine, Oncology, Pathology +14

What hides behind the MASC: clinical response and acquired resistance to entrectinib after ETV6-NTRK3 identification in a mammary analogue secretory carcinoma (MASC)

Alexander Drilon, G. Li, Snjezana Doğan et al. · Annals of Oncology · 2016 · 302 citations · Full text

Medicine, Oncology, Pharmacology +17

Molecular Profiling of Mammary Analog Secretory Carcinoma Revealed a Subset of Tumors Harboring a Novel ETV6-RET Translocation

Alena Skálová, Tomáš Vaněček, Petr Martínek et al. · The American Journal of Surgical Pathology · 2017 · 171 citations

Medicine, Cancer Biology, Oncology +13